2020 ASCO Virtual Scientific Meeting*

May 29-31, 2020; Online at meetings.asco.org/am
Review slidesets and expert analyses of key data from the 2020 Clinical Oncology Virtual Scientific Meeting!

Lung Cancer

Capsule Summary Slidesets

Combined treatment with lurbinectedin and irinotecan yields promising early antitumor activity in small-cell lung cancer, with an ORR of 69.2% in 13 evaluable patients.

Released: June 4, 2020

Pembrolizumab added to first-line therapy with etoposide and platinum chemotherapy for extensive-stage SCLC significantly improved PFS in the final analysis of KEYNOTE-604.

Released: June 1, 2020

Updated analysis finds durvalumab + EP maintains significant OS improvement vs EP alone with no further benefit with addition of tremelimumab.

Released: June 1, 2020

At a median follow-up of 80 months, adjuvant gefitinib significantly improved DFS but not OS vs vinorelbine/cisplatin in Chinese patients with completely resected stage IIA-IIIA (N1-N2) EGFR-mutated NSCLC.

Released: June 9, 2020

Chemotherapy-free treatment with first-line nivolumab and ipilimumab continues to provide durable clinical benefit to patients with advanced NSCLC, regardless of tumor PD-L1 expression.

Released: June 1, 2020

Nivolumab + ipilimumab + 2 cycles of chemotherapy improved OS vs 4 cycles of chemotherapy alone as first-line therapy for patients with advanced NSCLC.

Released: June 2, 2020

Dual immune checkpoint inhibition with tiragolumab plus atezolizumab achieved meaningful improvement in ORR and PFS with comparable safety vs placebo plus atezolizumab, with the greatest benefit among patients with PD-L1 TPS ≥ 50%.

Released: June 5, 2020

T-DXd was associated with a high response rate and durable responses with no new safety signals in previously treated patients with HER2-mutated NSCLC.

Released: May 30, 2020

Addition of SBRT to first-line EGFR TKI significantly prolonged PFS and OS vs EGFR TKI alone in Chinese patients with EGFR-mutated oligometastatic NSCLC.

Released: June 5, 2020

Capmatinib was associated with deep responses in both treatment-naive and previously treated patients with NSCLC and high-level MET amplification (GCN ≥ 10).

Released: June 4, 2020

Pralsetinib associated with a high ORR, intracranial activity, and durable responses in patients with RET fusion–positive NSCLC regardless of prior treatment or RET fusion partner.

Released: June 8, 2020

Patients who were platinum sensitive during first-line platinum therapy more likely to respond to second-line liposomal irinotecan than those who were platinum resistant.

Released: June 3, 2020

Adjuvant osimertinib associated with significantly improved disease-free survival after complete resection in patients with stage IB/II/IIIA EGFR-mutated NSCLC.

Released: June 1, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Pharma
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?